Identification of novel macropinocytosis inhibitors using a rational screen of Food and Drug Administration‐approved drugs

Background and Purpose Macropinocytosis is involved in many pathologies, including cardiovascular disorders, cancer, allergic diseases, viral and bacterial infections. Unfortunately, the currently available pharmacological inhibitors of macropinocytosis interrupt other endocytic processes and have non‐specific endocytosis‐independent effects. Here we have sought to identify new, clinically relevant inhibitors of macropinocytosis, using an FDA‐approved drug library.